[1] 庄 辉. ALD 的流行病学[J]. 中华肝脏病杂志, 2003, 11: 698.
[2] 全国酒精性肝病调查协作组. 全国酒精性肝病的多中心调查分析[J]. 中华消化杂志 2007; 27: 231.
[3] 中国药典[M]. 2005版1部. 2005: 364.
[4] Chen ML, Tsai SH, Ip SP, et al. Long-term treatment with a "Yang-Invigorating" Chinese herbal formula, WuZi-YanZongWan, reduces mortality and liver oxidative damage in chronic alcohol-Intoxicated rats[J]. Rejuv Res, 2010, 13: 459.
[5] Chen ML, Ip SP, Tsai SH, et al. Biochemical mechanism of Wu-Zi-Yan-Zong-Wan, a traditional Chinese herbal formula, against alcohol-induced oxidative damage in CYP2E1 cDNA-transfected HepG2 (E47) cells[J]. J Ethnopharmacol, 2010, 128: 116.
[6] Ronis MJ, Hakkak R, Korourian S, et al. Alcoholic liver disease in rats fed ethanol as part of oral or intragastric low-carbohydrate liquid diets[J]. Exp Biol Med 2004; 229: 351.
[7] Albano E. New concepts in the pathogenesis of alcoholic liver disease[J]. Expert Rev Gastroenterol Hepatol 2008; 2:749.
[8] Arteel GE. Oxidants and antioxidants in chronic alcoholic liver disease[J]. Gastroenterology, 2003, 124: 778.
[9] Hanck C, Rossol S, Bocker U, et al. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis[J]. Alcohol Alcoholism, 1998, 33:606.
[10] Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases[J]. Gastroenterology, 1992, 103: 264.
[11] Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-α monoclonal antibody therapy in severe alcoholic hepatitis[J]. J Hepatol, 2003, 38: 419.
[12] Menon K, Stadheim L, Kamath P, et al. Safety and tolerability of etanercept in patients with alcoholic hepatitis[J]. Am J Gastroenterol, 2004, 99: 255.
[13] Spahr L, Rubbia-Brandt L, Frossard J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study[J]. J Hepatol, 2002, 37: 448.